Literature DB >> 33777498

Tardive Blepharospasm May Respond to Bilateral Pallidal Deep Brain Stimulation.

Virgilio Gerald H Evidente1, Francisco A Ponce2, Maris H Evidente1, Margaret Lambert1, Robin Garrett1.   

Abstract

Background: To date, there have been no reports of tardive blepharospasm being treated with deep brain stimulation (DBS), though there have been two reports of focal blepharospasm responding favorably to bilateral pallidal DBS. Case: A 34 year old man with tardive blepharospasm that was refractory to oral medications as well as botulinum toxin types A and B underwent bilateral pallidal DBS under general anesthesia. He had significant improvement of his severe blepharospasm by one and half months post-DBS which was sustained at last follow-up 30 months post-DBS. The best programming parameters included pulse widths of 90-100 µsec, frequencies of 140-150 Hz, and stimulating the ventral contacts in each side.
Conclusion: Our case represents the first report of medically refractory tardive blepharospasm responding favorably to bilateral pallidal DBS. Copyright:
© 2021 The Author(s).

Entities:  

Keywords:  Blepharospasm; DBS; GPi; Tardive; deep brain stimulation; pallidal DBS

Mesh:

Year:  2021        PMID: 33777498      PMCID: PMC7977745          DOI: 10.5334/tohm.594

Source DB:  PubMed          Journal:  Tremor Other Hyperkinet Mov (N Y)        ISSN: 2160-8288


  13 in total

1.  Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox.

Authors:  Jonathan J Dutton; Jeffrey J White; Michael J Richard
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2006 May-Jun       Impact factor: 1.746

Review 2.  Long-term follow-up of deep brain stimulation for Meige syndrome.

Authors:  Mark K Lyons; Barry D Birch; Renee A Hillman; Orland K Boucher; Virgilio Gerald H Evidente
Journal:  Neurosurg Focus       Date:  2010-08       Impact factor: 4.047

3.  IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.

Authors:  Virgilio Gerald H Evidente; Daniel Truong; Joseph Jankovic; Cynthia L Comella; Susanne Grafe; Angelika Hanschmann
Journal:  J Neurol Sci       Date:  2014-08-10       Impact factor: 3.181

Review 4.  Hemifacial spasm and other craniofacial movement disorders.

Authors:  V G Evidente; C H Adler
Journal:  Mayo Clin Proc       Date:  1998-01       Impact factor: 7.616

5.  Deep brain stimulation for Meige syndrome: a meta-analysis with individual patient data.

Authors:  Xin Wang; Zhibin Zhang; Zhiqi Mao; Xinguang Yu
Journal:  J Neurol       Date:  2019-07-13       Impact factor: 4.849

6.  Deep brain stimulation effects in dystonia: time course of electrophysiological changes in early treatment.

Authors:  Diane Ruge; Stephen Tisch; Marwan I Hariz; Ludvic Zrinzo; Kailash P Bhatia; Niall P Quinn; Marjan Jahanshahi; Patricia Limousin; John C Rothwell
Journal:  Mov Disord       Date:  2011-05-05       Impact factor: 10.338

7.  Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease.

Authors:  Tsinsue Chen; Zaman Mirzadeh; Kristina M Chapple; Margaret Lambert; Holly A Shill; Guillermo Moguel-Cobos; Alexander I Tröster; Rohit Dhall; Francisco A Ponce
Journal:  J Neurosurg       Date:  2018-03-16       Impact factor: 5.115

Review 8.  Botulinum toxin in the treatment of blepharospasm and hemifacial spasm.

Authors:  C Kenney; J Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2007-06-11       Impact factor: 3.575

9.  Pallidal stimulation for medically intractable blepharospasm.

Authors:  Kazumichi Yamada; Naoki Shinojima; Tadashi Hamasaki; Jun-ichi Kuratsu
Journal:  BMJ Case Rep       Date:  2016-03-31

10.  Effects of pulse width variations in pallidal stimulation for primary generalized dystonia.

Authors:  Laurent Vercueil; Jean Luc Houeto; Pierre Krystkowiak; Christelle Lagrange; François Cassim; Abdelhamid Benazzouz; Bernard Pidoux; Alain Destée; Yves Agid; Philippe Cornu; Serge Blond; Alim Louis Benabid; Pierre Pollak; Marie Vidailhet
Journal:  J Neurol       Date:  2007-06-29       Impact factor: 6.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.